OCUP Stock Forecast 2025-2026
Distance to OCUP Price Targets
OCUP Price Momentum
10 Quality Stocks Worth Considering Now
Researching Ocuphire (OCUP) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on OCUP and similar high-potential opportunities.
Latest OCUP Stock Price Targets & Analyst Predictions
OCUP has shown a year-to-date change of -26.2% and a 1-year change of -51.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for OCUP. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OCUP Analyst Ratings
OCUP Price Target Range
Latest OCUP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OCUP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 23, 2024 | Canaccord Genuity | John Newman | Buy | Maintains | $10.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $18.00 |
| Aug 14, 2024 | Canaccord Genuity | John Newman | Buy | Maintains | $18.00 |
| May 13, 2024 | Canaccord Genuity | John Newman | Buy | Maintains | $18.00 |
| May 13, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $20.00 |
| Mar 20, 2024 | Alliance Global Partners | James Molloy | Buy | Maintains | $20.00 |
| Mar 11, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $20.00 |
| Nov 14, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $20.00 |
| Aug 14, 2023 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $17.00 |
| Aug 14, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $20.00 |
| May 16, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $20.00 |
| Mar 31, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $20.00 |
| Feb 17, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $20.00 |
| Jan 26, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $20.00 |
| Nov 24, 2021 | HC Wainwright & Co. | Andrew Fein | Buy | Initiates | $26.00 |
| Apr 5, 2021 | Alliance Global Partners | Buy | Initiates | $0.00 | |
| Mar 29, 2021 | JonesTrading | Buy | Initiates | $0.00 | |
| Mar 15, 2021 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $20.00 |
| Feb 10, 2021 | Canaccord Genuity | Buy | Initiates | $0.00 | |
| Nov 20, 2020 | Cantor Fitzgerald | Overweight | Initiates | $0.00 |
Opus Genetics Inc. (OCUP) Competitors
The following stocks are similar to Ocuphire based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Opus Genetics Inc. (OCUP) Financial Data
Opus Genetics Inc. has a market capitalization of $31.74M with a P/E ratio of 1.4x. The company generates $16.45M in trailing twelve-month revenue with a -85.8% profit margin.
Revenue growth is -69.7% quarter-over-quarter, while maintaining an operating margin of -748.9% and return on equity of -36.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Opus Genetics Inc. (OCUP) Business Model
About Opus Genetics Inc.
Develops gene therapies for inherited retinal diseases.
The company focuses on creating innovative gene therapies to address unmet medical needs in patients with inherited retinal diseases. By utilizing advanced techniques in gene therapy, Opus Genetics targets the root causes of vision disorders, thus generating revenue through the development and potential commercialization of these specialized treatments.
Opus Genetics operates at the intersection of genetic research, clinical development, and ophthalmology, positioning itself in a niche yet critical sector within biotechnology. The company's mission highlights the importance of breakthrough biomedical research in improving the quality of life for patients suffering from chronic vision impairments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
CEO
Mr. George Magrath M.B.A., M.D., M.S.
Country
United States
IPO Year
2008
Website
opusgtx.comOpus Genetics Inc. (OCUP) Latest News & Analysis
Ocuphire Pharma, Inc. (Nasdaq: OCUP) has acquired Opus Genetics, Inc. in an all-stock deal. The new entity will be named Opus Genetics and trade under the ticker symbol IRD.
The acquisition of Opus Genetics by Ocuphire Pharma could enhance Ocuphire's product pipeline and market position in the ophthalmic sector, potentially impacting stock performance.
An acquisition has formed a leading clinical-stage company dedicated to developing gene therapy treatments for rare inherited retinal degenerations.
The acquisition positions the company as a leader in a niche market, potentially increasing its valuation and attracting investment in innovative gene therapies.
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
4 months agoOcuphire Pharma, Inc. (OCUP) announced an all-stock acquisition of Opus Genetics, Inc., which focuses on gene therapy for inherited retinal diseases.
Ocuphire's acquisition of Opus Genetics may enhance its portfolio in gene therapy, potentially increasing value and market competitiveness, impacting stock performance and investor sentiment.
Ademi LLP is investigating Ocuphire (Nasdaq: OCUP) for potential fiduciary duty breaches in its deal with Opus Genetics, involving the issuance of 5.2 million common shares and 14.1K preferred shares.
Concerns over potential fiduciary breaches in Ocuphire's deal with Opus Genetics may affect investor confidence, stock price, and future fundraising efforts.
Phase 3 clinical trials show rapid reversal of pharmacologically-induced mydriasis with a favorable safety profile, indicating potential for marketable treatment options.
Successful Phase 3 trial results suggest potential market approval for a new treatment, which could boost the company's revenue and stock performance, indicating growth potential for investors.
Ocuphire Pharma has initiated dosing in the VEGA-3 Phase 3 trial for Phentolamine Ophthalmic Solution 0.75% for presbyopia. Top-line data from this trial is expected in H1 2025.
The upcoming Phase 3 trial data for Ocuphire Pharma's therapies could significantly impact its stock price and market perception, influencing investment decisions in the biotech sector.
Frequently Asked Questions About OCUP Stock
What is Opus Genetics Inc.'s (OCUP) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Opus Genetics Inc. (OCUP) has a median price target of $11.00. The highest price target is $20.00 and the lowest is $10.00.
Is OCUP stock a good investment in 2025?
Analyst ratings for OCUP are not currently available. The stock is currently trading at $0.93. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OCUP stock?
Wall Street analysts predict OCUP stock could reach $11.00 in the next 12 months. This represents a 1,076.6% increase from the current price of $0.93. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Opus Genetics Inc.'s business model?
The company focuses on creating innovative gene therapies to address unmet medical needs in patients with inherited retinal diseases. By utilizing advanced techniques in gene therapy, Opus Genetics targets the root causes of vision disorders, thus generating revenue through the development and potential commercialization of these specialized treatments.
What is the highest forecasted price for OCUP Opus Genetics Inc.?
The highest price target for OCUP is $20.00 from Matthew Caufield at HC Wainwright & Co., which represents a 2,039.3% increase from the current price of $0.93.
What is the lowest forecasted price for OCUP Opus Genetics Inc.?
The lowest price target for OCUP is $10.00 from John Newman at Canaccord Genuity, which represents a 969.6% increase from the current price of $0.93.
What is the overall OCUP consensus from analysts for Opus Genetics Inc.?
Analyst ratings for OCUP are not currently available. The stock is trading at $0.93.
How accurate are OCUP stock price projections?
Stock price projections, including those for Opus Genetics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
